XML 18 R9.htm IDEA: XBRL DOCUMENT v3.25.2
Related Party Transactions
9 Months Ended
Jul. 31, 2025
Related Party Transactions [Abstract]  
Related Party Transactions
4. Related Party Transactions

 

  a. Compensation to key management personnel

 

  (i) The compensation to key management personnel for services they provide to the Company is as follows:

 

   Three months
ended
   Three months
ended
   Nine months
ended
   Nine months
ended
 
   July 31,   July 31,   July 31,   July 31, 
   2025   2024   2025   2024 
Officers:                
Consulting fees  $87,496   $86,792   $256,053   $335,066 
Share based compensation   
-
    103,977    117,902    251,717 
   $87,496   $190,769   $373,955   $586,783 
Directors:                    
Directors’ fees  $69,663   $88,538   $245,996   $274,063 
Share based compensation   
-
    105,957    195,101    352,879 
   $69,663   $194,495   $441,097   $626,942 

 

  (ii) Balances with related parties

 

   July 31,   October 31, 
   2025   2024 
Amounts owed to officers  $29,948   $29,498 
Amounts owed to directors   19,872    19,464 
   $49,820   $48,962 

  

  b.

On March 7, 2022, the Company signed an agreement with SciSparc Ltd (“SciSparc”), pursuant to which the Company and SciSparc agreed to cooperate in conducting a feasibility study using certain molecules developed by each party (the “Cooperation Agreement”). Certain of the Company’s officers and directors currently operate, manage or are engaged as officers and/or directors of SciSparc.

 

In June 2023, the Company entered into a research agreement with the Hebrew University of Jerusalem to evaluate SciSparc’s and the Company’s combination treatment for obesity and metabolic syndrome.

 

To date, the collaboration has resulted in the filing of nine patent applications. To the extent the parties determine to proceed to a commercial cooperation, they may enter into a joint venture by the parties share the economics and rights on a 50%-50% basis. To date, no determination has been made to pursue the joint venture as the development of the project remains at a very early stage.

 

For the three and nine months ended July 31, 2025, the Company incurred research and development expenses conducted within the framework of the Cooperation Agreement in the amount of $39,270 and $85,779, respectively (three and nine months ended July 31, 2024- $4,080 and $26,888 respectively). As of July 31, 2025, $174,043 is owed to the Company by SciSparc (October 31, 2024 - $131,839 owed to the Company).

  

  c. On June 13, 2024, the Company entered into an agreement with SciSparc for the lease of office space in Tel Aviv, Israel, having a total area of approximately 386 square meters. The Company occupies approximately 193 square meters of the space for its offices. The rental period is from April 1, 2024 to March 31, 2026. The Company’s base rent was ILS 12,500 per month (approximately $3,400) during the term of the lease. The lease liability was discounted using the Company’s estimated incremental annual borrowing rate of 10%.